Neurological features of Fabry disease: Clinical, pathophysiological aspects and therapy

A. Bersano, S. Lanfranconi, C. Valcarenghi, N. Bresolin, G. Micieli, P. Baron

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Fabry disease is a multisystem, Xlinked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alphagalactosidase A enzyme (αGal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.

Original languageEnglish
Pages (from-to)77-97
Number of pages21
JournalActa Neurologica Scandinavica
Volume126
Issue number2
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Fabry Disease
Enzyme Replacement Therapy
Peripheral Nervous System
Neurologic Manifestations
Diagnostic Errors
Chronic Kidney Failure
Differential Diagnosis
Therapeutics
Central Nervous System
Heart Failure
Chromosomes
Stroke
Mutation
Enzymes
Genes

Keywords

  • Enzyme replacement therapy
  • Fabry disease
  • Neurological aspects
  • Neuropathy
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Neurological features of Fabry disease : Clinical, pathophysiological aspects and therapy. / Bersano, A.; Lanfranconi, S.; Valcarenghi, C.; Bresolin, N.; Micieli, G.; Baron, P.

In: Acta Neurologica Scandinavica, Vol. 126, No. 2, 08.2012, p. 77-97.

Research output: Contribution to journalArticle

@article{0aa5023c9eb54ef4ba1ea61d5cde8afa,
title = "Neurological features of Fabry disease: Clinical, pathophysiological aspects and therapy",
abstract = "Fabry disease is a multisystem, Xlinked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alphagalactosidase A enzyme (αGal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.",
keywords = "Enzyme replacement therapy, Fabry disease, Neurological aspects, Neuropathy, Stroke",
author = "A. Bersano and S. Lanfranconi and C. Valcarenghi and N. Bresolin and G. Micieli and P. Baron",
year = "2012",
month = "8",
doi = "10.1111/j.1600-0404.2012.01661.x",
language = "English",
volume = "126",
pages = "77--97",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",
number = "2",

}

TY - JOUR

T1 - Neurological features of Fabry disease

T2 - Clinical, pathophysiological aspects and therapy

AU - Bersano, A.

AU - Lanfranconi, S.

AU - Valcarenghi, C.

AU - Bresolin, N.

AU - Micieli, G.

AU - Baron, P.

PY - 2012/8

Y1 - 2012/8

N2 - Fabry disease is a multisystem, Xlinked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alphagalactosidase A enzyme (αGal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.

AB - Fabry disease is a multisystem, Xlinked, lysosomal storage disorder caused by a mutation in the GLA gene on chromosome Xq22 resulting in alphagalactosidase A enzyme (αGal A) deficiency. Neurological manifestations other than cerebrovascular accidents include small fibre neuropathy and dysautonomic disorders, which may be the presenting clinical features in a proportion of patients. An atypical disease onset may be misdiagnosed until the emergence of a more typical clinical picture, characterized by chronic renal and cardiac failure. Thus, neurologists should consider Fabry disease in differential diagnosis and provide an appropriate diagnostic work up. This review focuses on central and peripheral nervous system involving available diagnostic tools and diagnostic work up in Fabry disease. It also covers the most recent evidence regarding enzyme replacement therapy.

KW - Enzyme replacement therapy

KW - Fabry disease

KW - Neurological aspects

KW - Neuropathy

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84863452623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863452623&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0404.2012.01661.x

DO - 10.1111/j.1600-0404.2012.01661.x

M3 - Article

C2 - 22428782

AN - SCOPUS:84863452623

VL - 126

SP - 77

EP - 97

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 2

ER -